Editas Medicine (EDIT)
Editas Medicine on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
38.2M
Short interest
settlement 2026-10-15
14.3
Days to cover
+5.0 days vs prior
60.7%
Short share of volume
2026-11-02
85
Fails to deliver
settlement 2026-10-14
Mon 9 Nov
Next earnings
estimated date
-$19K
Insider flow, 90 days
0 buys, 3 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in EDIT is 38,185,007 shares, up 8,220,814 shares over the last month. Over the last 48 readings it ranged from 7,456,270 shares (30 September 2025) to 38,185,007 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 2.7M shares a day that is 14.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/edit" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 38,185,007 | +2.9% | 2,662,723 | 14.34 |
| 2026-09-30 | 37,109,260 | +23.9% | 3,970,413 | 9.35 |
| 2026-09-15 | 29,964,193 | -0.9% | 1,906,017 | 15.72 |
| 2026-08-31 | 30,232,239 | +22.5% | 3,372,729 | 8.96 |
| 2026-08-14 | 24,686,466 | +5.2% | 1,692,123 | 14.59 |
| 2026-07-31 | 23,464,219 | +5.7% | 1,289,898 | 18.19 |
| 2026-07-15 | 22,197,638 | -1.2% | 2,766,681 | 8.02 |
| 2026-06-30 | 22,473,029 | +22.0% | 3,116,110 | 7.21 |
| 2026-06-15 | 18,414,894 | +22.2% | 2,390,764 | 7.70 |
| 2026-05-29 | 15,066,130 | +57.6% | 4,478,910 | 3.36 |
| 2026-05-15 | 9,561,026 | -4.5% | 1,116,594 | 8.56 |
| 2026-04-30 | 10,007,345 | -8.3% | 1,415,098 | 7.07 |
| 2026-04-15 | 10,915,607 | -8.6% | 1,684,449 | 6.48 |
| 2026-03-31 | 11,941,373 | +3.6% | 1,384,934 | 8.62 |
| 2026-03-13 | 11,522,947 | -3.1% | 2,272,804 | 5.07 |
| 2026-02-27 | 11,890,283 | +1.2% | 1,449,253 | 8.20 |
| 2026-02-13 | 11,747,144 | +2.5% | 1,469,564 | 7.99 |
| 2026-01-30 | 11,464,526 | -3.1% | 1,875,153 | 6.11 |
| 2026-01-15 | 11,829,004 | +4.5% | 1,959,829 | 6.04 |
| 2025-12-31 | 11,320,572 | +1.5% | 1,741,224 | 6.50 |
| 2025-12-15 | 11,154,083 | +5.5% | 1,753,452 | 6.36 |
| 2025-11-28 | 10,568,381 | +5.6% | 1,341,342 | 7.88 |
| 2025-11-14 | 10,005,943 | +15.5% | 2,006,151 | 4.99 |
| 2025-10-31 | 8,665,653 | +13.7% | 2,919,107 | 2.97 |
| 2025-10-15 | 7,619,416 | +2.2% | 3,508,259 | 2.17 |
| 2025-09-30 | 7,456,270 | -1.4% | 3,165,097 | 2.36 |
| 2025-09-15 | 7,561,998 | -3.3% | 1,388,956 | 5.44 |
| 2025-08-29 | 7,815,797 | -4.7% | 1,073,735 | 7.28 |
| 2025-08-15 | 8,202,599 | +4.5% | 2,261,509 | 3.63 |
| 2025-07-31 | 7,852,628 | -7.8% | 2,626,886 | 2.99 |
| 2025-07-15 | 8,516,241 | -2.5% | 3,414,800 | 2.49 |
| 2025-06-30 | 8,730,833 | +3.6% | 3,187,306 | 2.74 |
| 2025-06-13 | 8,426,415 | -6.3% | 2,240,934 | 3.76 |
| 2025-05-30 | 8,997,908 | -1.0% | 1,694,684 | 5.31 |
| 2025-05-15 | 9,091,921 | -21.7% | 1,898,180 | 4.79 |
| 2025-04-30 | 11,609,743 | -8.3% | 1,597,517 | 7.27 |
| 2025-04-15 | 12,667,355 | -0.1% | 2,510,939 | 5.04 |
| 2025-03-31 | 12,684,584 | -3.5% | 1,748,783 | 7.25 |
| 2025-03-14 | 13,149,670 | -4.5% | 3,161,976 | 4.16 |
| 2025-02-28 | 13,766,088 | -21.1% | 12,129,227 | 1.13 |
| 2025-02-14 | 17,438,018 | +2.0% | 2,120,794 | 8.22 |
| 2025-01-31 | 17,089,279 | -10.8% | 2,105,504 | 8.12 |
| 2025-01-15 | 19,150,654 | +5.2% | 2,856,435 | 6.70 |
| 2024-12-31 | 18,207,713 | +7.5% | 3,021,371 | 6.03 |
| 2024-12-13 | 16,929,351 | +5.4% | 3,308,274 | 5.12 |
| 2024-11-29 | 16,060,625 | +1.0% | 2,659,904 | 6.04 |
| 2024-11-15 | 15,905,551 | -7.7% | 2,246,473 | 7.08 |
| 2024-10-31 | 17,239,218 | -6.0% | 1,950,382 | 8.84 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of EDIT volume is 60.7%, down 6.9 points over the last five sessions. Over the last 30 readings it ranged from 25.3% (19 October 2026) to 76.3% (5 October 2026). The latest reading is 6.1 points above the 30-session average of 54.5%, on 401K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 243K | 401K | 60.7% | 19,699 |
| 2026-10-30 | 706K | 1.4M | 49.6% | 42,798 |
| 2026-10-29 | 435K | 1.3M | 34.1% | 0 |
| 2026-10-28 | 684K | 2.0M | 34.5% | 0 |
| 2026-10-27 | 715K | 1.3M | 55.3% | 0 |
| 2026-10-26 | 416K | 616K | 67.5% | 48 |
| 2026-10-23 | 364K | 549K | 66.2% | 3,423 |
| 2026-10-22 | 266K | 399K | 66.7% | 1,480 |
| 2026-10-21 | 234K | 432K | 54.2% | 3 |
| 2026-10-20 | 368K | 855K | 43.0% | 7,532 |
| 2026-10-19 | 216K | 856K | 25.3% | 0 |
| 2026-10-16 | 408K | 616K | 66.3% | 1,279 |
| 2026-10-15 | 632K | 959K | 65.9% | 5,130 |
| 2026-10-14 | 815K | 1.4M | 58.0% | 105,334 |
| 2026-10-13 | 595K | 1.1M | 53.2% | 16,784 |
| 2026-10-12 | 340K | 520K | 65.4% | 190 |
| 2026-10-09 | 465K | 1.3M | 36.2% | 819 |
| 2026-10-08 | 1.1M | 2.2M | 49.1% | 2,319 |
| 2026-10-07 | 681K | 997K | 68.3% | 198 |
| 2026-10-06 | 799K | 1.2M | 65.6% | 0 |
| 2026-10-05 | 1.2M | 1.6M | 76.3% | 0 |
| 2026-10-02 | 738K | 1.0M | 72.3% | 0 |
| 2026-10-01 | 262K | 576K | 45.4% | 1,316 |
| 2026-09-30 | 305K | 651K | 46.8% | 20 |
| 2026-09-29 | 367K | 637K | 57.6% | 1,206 |
| 2026-09-28 | 583K | 1.3M | 45.5% | 5,777 |
| 2026-09-25 | 613K | 1.8M | 34.7% | 682 |
| 2026-09-24 | 710K | 1.2M | 57.2% | 88 |
| 2026-09-23 | 1.6M | 2.3M | 68.7% | 2,642 |
| 2026-09-22 | 422K | 918K | 45.9% | 5,973 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in EDIT is 85 shares, down 9,760 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (2 June 2026) to 100,000 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 85 | $2.45 | $208 |
| 2026-10-13 | 9,845 | $2.75 | $27K |
| 2026-09-24 | 301 | $2.69 | $810 |
| 2026-09-22 | 180 | $2.83 | $509 |
| 2026-09-18 | 684 | $2.72 | $2K |
| 2026-09-16 | 2,048 | $2.63 | $5K |
| 2026-09-10 | 57,754 | $2.77 | $160K |
| 2026-09-09 | 2,387 | $3.03 | $7K |
| 2026-09-04 | 56 | $3.08 | $172 |
| 2026-08-25 | 41 | $3.00 | $123 |
| 2026-08-24 | 3,932 | $3.11 | $12K |
| 2026-07-28 | 686 | $2.68 | $2K |
| 2026-07-23 | 237 | $2.78 | $659 |
| 2026-07-17 | 2,082 | $2.88 | $6K |
| 2026-07-15 | 1,813 | $3.16 | $6K |
| 2026-07-14 | 336 | $3.16 | $1K |
| 2026-07-08 | 2,097 | $3.75 | $8K |
| 2026-07-02 | 113 | $3.28 | $371 |
| 2026-07-01 | 300 | $3.24 | $972 |
| 2026-06-30 | 100,000 | $3.20 | $320K |
| 2026-06-22 | 1,495 | $2.69 | $4K |
| 2026-06-16 | 90 | $2.46 | $221 |
| 2026-06-15 | 3,524 | $2.50 | $9K |
| 2026-06-10 | 1,383 | $2.65 | $4K |
| 2026-06-02 | 1 | $3.34 | $3 |
| 2026-06-01 | 45 | $3.46 | $156 |
| 2026-05-28 | 825 | $3.57 | $3K |
| 2026-05-27 | 1,967 | $3.08 | $6K |
| 2026-05-19 | 8 | $2.53 | $20 |
| 2026-05-18 | 1,065 | $2.62 | $3K |
Insider trades
SEC Form 4, newest first. JSONInsiders at EDIT reported 3 open-market sells worth $19K in the last 90 days and no open-market buys. Latest filing: Parison Amy (SVP, Chief Financial Officer) on 2026-09-03.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | Parison Amy | SVP, Chief Financial Officer | Sell | 453 | $3.04 | $1K | 14K |
| 2026-09-03 | O'Neill Gilmore Neil | CEO | Sell | 5K | $3.04 | $16K | 243K |
| 2026-09-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 709 | $3.04 | $2K | 62K |
| 2026-08-03 | Parison Amy | SVP, Chief Financial Officer | Sell | 678 | $2.58 | $2K | 14K |
| 2026-07-28 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 5K | $2.67 | $13K | 62K |
| 2026-06-03 | Parison Amy | SVP, Chief Financial Officer | Sell | 464 | $2.70 | $1K | 15K |
| 2026-06-03 | O'Neill Gilmore Neil | CEO | Sell | 15K | $2.70 | $42K | 248K |
| 2026-06-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 731 | $2.70 | $2K | 67K |
| 2026-03-03 | O'Neill Gilmore Neil | CEO | Sell | 5K | $2.02 | $11K | 264K |
| 2026-03-03 | Parison Amy | SVP, Chief Financial Officer | Sell | 474 | $2.02 | $957 | 15K |
| 2026-03-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 749 | $2.02 | $2K | 68K |
| 2025-12-03 | O'Neill Gilmore Neil | CEO | Sell | 6K | $2.15 | $12K | 269K |
| 2025-12-03 | Parison Amy | SVP, Chief Financial Officer | Sell | 461 | $2.15 | $993 | 16K |
| 2025-12-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 713 | $2.15 | $2K | 69K |
| 2025-09-03 | Parison Amy | SVP, Chief Financial Officer | Sell | 458 | $2.60 | $1K | 16K |
| 2025-09-03 | O'Neill Gilmore Neil | CEO | Sell | 6K | $2.60 | $15K | 275K |
| 2025-09-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 710 | $2.60 | $2K | 69K |
| 2025-08-07 | Parison Amy | SVP, Chief Financial Officer | Sell | 679 | $2.58 | $2K | 17K |
| 2025-07-31 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 5K | $2.49 | $13K | 64K |
| 2025-06-03 | O'Neill Gilmore Neil | CEO | Sell | 15K | $1.72 | $26K | 280K |
| 2025-06-03 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 726 | $1.72 | $1K | 70K |
| 2025-06-03 | Parison Amy | SVP, Chief Financial Officer | Sell | 446 | $1.72 | $767 | 18K |
| 2025-03-04 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 3K | $1.71 | $5K | 70K |
| 2025-03-04 | O'Neill Gilmore Neil | CEO | Sell | 17K | $1.71 | $28K | 295K |
| 2025-03-04 | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | Sell | 4K | $1.71 | $7K | 113K |
| 2024-12-03 | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | Sell | 541 | $2.08 | $1K | 133K |
| 2024-12-03 | O'Neill Gilmore Neil | CEO | Sell | 2K | $2.08 | $3K | 312K |
| 2024-09-04 | O'Neill Gilmore Neil | CEO | Sell | 2K | $3.42 | $5K | 314K |
| 2024-09-04 | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | Sell | 518 | $3.42 | $2K | 134K |
| 2024-07-25 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 12K | $5.42 | $64K | 73K |
| 2024-07-19 | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | Sell | 7K | $5.21 | $34K | 134K |
| 2024-06-04 | Mei Baisong | EVP, CHIEF MEDICAL OFFICER | Sell | 511 | $5.50 | $3K | 141K |
| 2024-06-04 | O'Neill Gilmore Neil | CEO | Sell | 12K | $5.50 | $67K | 315K |
| 2024-05-20 | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | Sell | 22K | $5.61 | $125K | 117K |
| 2024-05-13 | Hopfield Jessica | Director | Buy | 45K | $5.64 | $254K | 68K |
| 2024-03-05 | O'Neill Gilmore Neil | CEO | Sell | 78K | $9.42 | $733K | 327K |
| 2024-03-04 | Mei Baisong | SVP, CHIEF MEDICAL OFFICER | Sell | 20K | $9.42 | $191K | 142K |
| 2024-03-02 | Mei Baisong | SVP, CHIEF MEDICAL OFFICER | Grant | 19K | $0.00 | $0 | 142K |
| 2024-03-02 | Mei Baisong | SVP, CHIEF MEDICAL OFFICER | Grant | 19K | $0.00 | $0 | 162K |
| 2024-03-02 | Mei Baisong | SVP, CHIEF MEDICAL OFFICER | Grant | 51K | $0.00 | $0 | 123K |
| 2024-03-02 | O'Neill Gilmore Neil | CEO | Grant | 131K | $0.00 | $0 | 261K |
| 2024-03-02 | O'Neill Gilmore Neil | CEO | Grant | 72K | $0.00 | $0 | 333K |
| 2024-03-02 | O'Neill Gilmore Neil | CEO | Grant | 72K | $0.00 | $0 | 405K |
| 2024-03-02 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Grant | 15K | $0.00 | $0 | 85K |
| 2024-03-02 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Grant | 25K | $0.00 | $0 | 70K |
| 2024-03-02 | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | Grant | 26K | $0.00 | $0 | 139K |
| 2024-03-02 | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | Grant | 35K | $0.00 | $0 | 113K |
| 2023-12-05 | Eaton Bruce | EVP, CBO AND CTO | Sell | 103 | $10.90 | $1K | 75K |
| 2023-11-14 | Eaton Bruce | EVP, CBO AND CTO | Sell | 695 | $8.21 | $6K | 75K |
| 2023-11-07 | Eaton Bruce | EVP, CBO AND CTO | Sell | 139 | $8.40 | $1K | 76K |
| 2023-09-06 | Eaton Bruce | EVP, CBO AND CTO | Sell | 103 | $8.82 | $908 | 76K |
| 2023-08-11 | Eaton Bruce | EVP, CBO AND CTO | Sell | 702 | $8.59 | $6K | 76K |
| 2023-08-08 | Eaton Bruce | EVP, CBO AND CTO | Sell | 141 | $8.39 | $1K | 77K |
| 2023-07-24 | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | Grant | 45K | $0.00 | $0 | 45K |
| 2023-07-19 | Mei Baisong | SVP, CHIEF MEDICAL OFFICER | Sell | 4K | $8.80 | $38K | 72K |
| 2023-06-05 | Eaton Bruce | EVP, CBO AND CTO | Sell | 105 | $9.50 | $998 | 77K |
| 2023-06-05 | O'Neill Gilmore Neil | CEO | Sell | 6K | $9.50 | $62K | 130K |
| 2023-05-17 | Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | Grant | 78K | $0.00 | $0 | 78K |
| 2023-05-11 | Eaton Bruce | EVP, CBO AND CTO | Sell | 668 | $9.87 | $7K | 77K |
| 2023-05-11 | ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Sell | 949 | $9.87 | $9K | 107K |
| 2023-05-09 | Eaton Bruce | EVP, CBO AND CTO | Sell | 135 | $9.51 | $1K | 77K |
| 2023-03-03 | Eaton Bruce | EVP, CBO AND CTO | Sell | 101 | $8.89 | $898 | 78K |
| 2023-03-03 | ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Sell | 184 | $8.89 | $2K | 108K |
| 2023-03-02 | Eaton Bruce | EVP, CBO AND CTO | Grant | 17K | $0.00 | $0 | 78K |
| 2023-03-02 | O'Neill Gilmore Neil | CEO | Grant | 50K | $0.00 | $0 | 137K |
| 2023-03-02 | Mei Baisong | SVP, CHIEF MEDICAL OFFICER | Grant | 18K | $0.00 | $0 | 76K |
| 2023-03-02 | ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Grant | 32K | $0.00 | $0 | 108K |
| 2023-02-13 | Eaton Bruce | EVP, CBO AND CTO | Sell | 3K | $9.67 | $32K | 61K |
| 2023-02-13 | ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Sell | 4K | $9.67 | $41K | 76K |
| 2023-02-13 | Shearman Mark S | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 3K | $9.67 | $27K | 66K |
| 2023-02-07 | Eaton Bruce | EVP, CBO AND CTO | Sell | 346 | $11.10 | $4K | 64K |
| 2023-01-10 | ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Sell | 2K | $8.16 | $14K | 81K |
| 2022-12-05 | Eaton Bruce | EVP, CHIEF BUSINESS OFFICER | Sell | 102 | $10.23 | $1K | 65K |
| 2022-12-05 | ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Sell | 193 | $10.23 | $2K | 82K |
| 2022-11-08 | Eaton Bruce | EVP, CHIEF BUSINESS OFFICER | Sell | 289 | $11.02 | $3K | 65K |
| 2022-09-06 | Eaton Bruce | EVP, CHIEF BUSINESS OFFICER | Sell | 101 | $15.01 | $2K | 65K |
| 2022-09-06 | ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Sell | 192 | $15.01 | $3K | 82K |
| 2022-08-09 | Eaton Bruce | EVP, CHIEF BUSINESS OFFICER | Sell | 293 | $18.60 | $5K | 65K |
| 2022-07-18 | Mei Baisong | SVP, CHIEF MEDICAL OFFICER | Grant | 58K | $0.00 | $0 | 58K |
| 2022-06-15 | Shearman Mark S | EVP, CHIEF SCIENTIFIC OFFICER | Sell | 5K | $10.06 | $52K | 68K |
| 2022-06-03 | ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Sell | 2K | $11.54 | $18K | 83K |
| 2022-06-03 | Eaton Bruce | EVP, CHIEF BUSINESS OFFICER | Sell | 1K | $11.54 | $13K | 65K |
| 2022-06-02 | O'Neill Gilmore Neil | CEO | Grant | 87K | $0.00 | $0 | 87K |
| 2022-05-09 | Eaton Bruce | EVP, CHIEF BUSINESS OFFICER | Sell | 297 | $13.11 | $4K | 67K |
| 2022-04-01 | Eaton Bruce | EVP, CHIEF BUSINESS OFFICER | Sell | 1K | $19.64 | $25K | 67K |
| 2022-03-03 | ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Sell | 767 | $17.33 | $13K | 84K |
| 2022-03-03 | Eaton Bruce | EVP, CHIEF BUSINESS OFFICER | Sell | 403 | $17.33 | $7K | 68K |
| 2022-02-10 | ROBERTSON MICHELLE | CHIEF FINANCIAL OFFICER | Grant | 53K | $0.00 | $0 | 85K |
| 2022-02-10 | Shearman Mark S | EVP, CHIEF SCIENTIFIC OFFICER | Grant | 32K | $0.00 | $0 | 73K |
| 2022-02-10 | Eaton Bruce | EVP, CHIEF BUSINESS OFFICER | Grant | 38K | $0.00 | $0 | 69K |
| 2022-02-08 | Eaton Bruce | EVP, CHIEF BUSINESS OFFICER | Sell | 302 | $17.63 | $5K | 31K |
| 2022-01-11 | ROBERTSON MICHELLE | Chief Financial Officer | Sell | 2K | $25.70 | $45K | 31K |
| 2022-01-03 | MULLEN JAMES C | CEO | Sell | 18K | $26.95 | $492K | 76K |
| 2021-12-22 | MULLEN JAMES C | CEO | Grant | 36K | $0.00 | $0 | 94K |
| 2021-12-22 | ROBERTSON MICHELLE | Chief Financial Officer | Grant | 4K | $0.00 | $0 | 33K |
| 2021-12-22 | Shearman Mark S | EVP, Chief Scientific Officer | Grant | 9K | $0.00 | $0 | 42K |
| 2021-12-22 | Michaels Lisa Anne | EVP/Chief Medical Officer | Grant | 4K | $0.00 | $0 | 23K |
| 2021-12-22 | Eaton Bruce | EVP, Chief Business Officer | Grant | 3K | $0.00 | $0 | 31K |
| 2021-11-12 | Michaels Lisa Anne | EVP/Chief Medical Officer | Sell | 2K | $38.33 | $60K | 18K |
| 2021-11-09 | Eaton Bruce | EVP, Chief Business Officer | Sell | 287 | $40.61 | $12K | 28K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON6 Form 144 notices on file for EDIT worth $110K at the prices reported; 2 in the last 90 days worth $19K. Latest: O'Neill Gilmore Neil filed on 2026-08-31 to sell 5,100 shares ($17K) from 2026-09-03.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-31 | O'Neill Gilmore NeilOfficer, Director | 5K | $17K | 0.003% | 2026-09-03 | E Trade Corporation |
| 2026-08-31 | Burkly LindaOfficer | 700 | $2K | 0.000% | 2026-09-03 | ETrade Corporation |
| 2026-07-21 | Burkly LindaOfficer | 6K | $16K | 0.004% | 2026-07-27 | ETrade Corporation |
| 2026-05-29 | O'Neill Gilmore NeilOfficer, Director | 15K | $46K | 0.015% | 2026-06-03 | ETrade Corporation |
| 2026-02-27 | O'Neill Gilmore NeilOfficer, Director | 6K | $11K | 0.006% | 2026-03-03 | ETrade Financial Corporation |
| 2025-12-01 | O'Neill Gilmore NeilOfficer, Director | 7K | $18K | 0.007% | 2025-12-03 | ETrade Financial Corporation |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON14 holders report 5% or more of EDIT in their latest filing, all on Schedule 13G (passive). The largest reported stake is Chen Yu at 9.9% of the class (15,798,999 shares), filed 2026-06-03 for an event on 2026-05-27.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G | BlackRock, Inc.parent holding company | 11.9M | 7.8% | 2026-09-30 |
| 2026-08-14 | 13G | ADAR1 Capital Management, LLCinvestment adviser, other entity | 8.9M | 5.8% | 2026-06-30 |
| 2026-08-14 | 13G | Daniel Schneebergerparent holding company, individual | 8.9M | 5.8% | 2026-06-30 |
| 2026-06-03 | 13G | RA Capital Management, L.P.investment adviser, partnership | 8.9M | 5.8% | 2026-05-27 |
| 2026-06-03 | 13G | RA Capital Healthcare Fund, L.P.partnership | 8.9M | 5.8% | 2026-05-27 |
| 2026-06-03 | 13G | Rajeev Shahparent holding company, individual | 8.9M | 5.8% | 2026-05-27 |
| 2026-06-03 | 13G | Peter Kolchinskyparent holding company, individual | 8.9M | 5.8% | 2026-05-27 |
| 2026-06-03 | 13G | Chen Yuindividual | 15.8M | 9.9% | 2026-05-27 |
| 2026-06-03 | 13G | TCG Crossover Fund III, L.P.partnership | 15.8M | 9.9% | 2026-05-27 |
| 2026-06-03 | 13G | TCG Crossover GP III, LLCother entity | 15.8M | 9.9% | 2026-05-27 |
| 2026-06-02 | 13G | Michael Kramarzparent holding company, individual | 16.0M | 9.9% | 2026-05-26 |
| 2026-06-02 | 13G | Robert Egen Atkinsonparent holding company, individual | 16.0M | 9.9% | 2026-05-26 |
| 2026-06-02 | 13G | Commodore Capital Master LPpartnership | 16.0M | 9.9% | 2026-05-26 |
| 2026-06-02 | 13G | Commodore Capital LPinvestment adviser, partnership | 16.0M | 9.9% | 2026-05-26 |
| 2026-03-26 | 13G/Ano. 10 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding EDIT at their latest 13F. JSON7 of the 30 tracked managers held EDIT at their latest 13F, $26.3M in total at quarter-end prices. Renaissance Technologies is the largest at $8.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 2.5M | $8.0M | 0.01% | -1.5M |
| D. E. Shaw & Co. | 2026-06-30 | 1.9M | $6.2M | 0.00% | -43K |
| AQR Capital Management | 2026-06-30 | 1.6M | $5.1M | 0.00% | +202K |
| Two Sigma Investments | 2026-06-30 | 1.3M | $4.3M | 0.00% | -216K |
| Millennium Management | 2026-06-30 | 499K | $1.6M | 0.00% | new |
| Citadel Advisors | 2026-06-30 | 213K | $689K | 0.00% | -450K |
| Point72 Asset Management | 2026-06-30 | 125K | $406K | 0.00% | +8K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Editas Medicine in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Editas Medicine (EDIT), SEC CIK 1650664, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-31.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-03.JSON and CSV
- Company record
- EDGAR filing index for CIK 1650664Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of EDIT is sold short?
38,185,007 shares were held short at the 2026-10-15 settlement, 14.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is EDIT's daily short volume?
On 2026-11-02, 243,237 of the 401,029 EDIT shares reported to FINRA were sold short, 60.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does EDIT have fails to deliver?
The SEC's latest file shows 85 EDIT shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are EDIT insiders buying or selling?
Insiders at EDIT reported 3 open-market sells worth $19K in the last 90 days and no open-market buys. Latest filing: Parison Amy (SVP, Chief Financial Officer) on 2026-09-03.
Have EDIT insiders filed to sell?
6 Form 144 notices on file for EDIT worth $110K at the prices reported; 2 in the last 90 days worth $19K. Latest: O'Neill Gilmore Neil filed on 2026-08-31 to sell 5,100 shares ($17K) from 2026-09-03.
Who owns 5% or more of EDIT?
14 holders report 5% or more of EDIT in their latest filing, all on Schedule 13G (passive). The largest reported stake is Chen Yu at 9.9% of the class (15,798,999 shares), filed 2026-06-03 for an event on 2026-05-27.
Which tracked 13F managers own EDIT?
7 of the 30 tracked 13F managers held EDIT shares at their latest filing, $26.3M in all. The largest: Renaissance Technologies (2.5M shares, $8.0M), D. E. Shaw & Co. (1.9M shares, $6.2M), Cliff Asness's AQR Capital Management (1.6M shares, $5.1M), Two Sigma Investments (1.3M shares, $4.3M), Izzy Englander's Millennium Management (499K shares, $1.6M), Ken Griffin's Citadel Advisors (213K shares, $689K). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.